Large oncosomes overexpressing integrin alpha-V promote prostate cancer adhesion and invasion via AKT activation.


Journal

Journal of experimental & clinical cancer research : CR
ISSN: 1756-9966
Titre abrégé: J Exp Clin Cancer Res
Pays: England
ID NLM: 8308647

Informations de publication

Date de publication:
18 Jul 2019
Historique:
received: 08 04 2019
accepted: 09 07 2019
entrez: 20 7 2019
pubmed: 20 7 2019
medline: 14 1 2020
Statut: epublish

Résumé

Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype. Immunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry. We found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status. Overall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.

Sections du résumé

BACKGROUND BACKGROUND
Molecular markers for prostate cancer (PCa) are required to improve the early definition of patient outcomes. Atypically large extracellular vesicles (EVs), referred as "Large Oncosomes" (LO), have been identified in highly migratory and invasive PCa cells. We recently developed and characterized the DU145R80 subline, selected from parental DU145 cells as resistant to inhibitors of mevalonate pathway. DU145R80 showed different proteomic profile compared to parental DU145 cells, along with altered cytoskeleton dynamics and a more aggressive phenotype.
METHODS METHODS
Immunofluorescence staining and western blotting were used to identify blebbing and EVs protein cargo. EVs, purified by gradient ultra-centrifugations, were analyzed by tunable resistive pulse sensing and multi-parametric flow cytometry approach coupled with high-resolution imaging technologies. LO functional effects were tested in vitro by adhesion and invasion assays and in vivo xenograft model in nude mice. Xenograft and patient tumor tissues were analyzed by immunohistochemistry.
RESULTS RESULTS
We found spontaneous blebbing and increased shedding of LO from DU145R80 compared to DU145 cells. LO from DU145R80, compared to those from DU145, carried increased amounts of key-molecules involved in PCa progression including integrin alpha V (αV-integrin). By incubating DU145 cells with DU145R80-derived LO we demonstrated that αV-integrin on LO surface was functionally involved in the increased adhesion and invasion of recipient cells, via AKT. Indeed either the pre-incubation of LO with an αV-integrin blocking antibody, or a specific AKT inhibition in recipient cells are able to revert the LO-induced functional effects. Moreover, DU145R80-derived LO also increased DU145 tumor engraftment in a mice model. Finally, we identified αV-integrin positive LO-like structures in tumor xenografts as well as in PCa patient tissues. Increased αV-integrin tumor expression correlated with high Gleason score and lymph node status.
CONCLUSIONS CONCLUSIONS
Overall, this study is the first to demonstrate the critical role of αV-integrin positive LO in PCa aggressive features, adding new insights in biological function of these large EVs and suggesting their potential use as PCa prognostic markers.

Identifiants

pubmed: 31319863
doi: 10.1186/s13046-019-1317-6
pii: 10.1186/s13046-019-1317-6
pmc: PMC6639931
doi:

Substances chimiques

Integrin alphaV 0
Proto-Oncogene Proteins c-akt EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

317

Subventions

Organisme : NCI NIH HHS
ID : R01 CA234557
Pays : United States
Organisme : Associazione Italiana per la Ricerca sul Cancro
ID : Fellowships AIRC-FIRC for Italy 19586
Organisme : Ministero della Salute
ID : Institutional Ricerca Corrente funds - Project M3_6

Références

FASEB J. 2001 Sep;15(11):1953-62
pubmed: 11532975
Int J Cancer. 2004 Dec 10;112(5):738-46
pubmed: 15386367
Endocr Relat Cancer. 2006 Mar;13(1):7-26
pubmed: 16601276
J Cell Biol. 2007 Jun 4;177(5):927-39
pubmed: 17548516
Int J Cancer. 2007 Oct 1;121(7):1424-32
pubmed: 17551921
Clin Cancer Res. 2008 Sep 15;14(18):5649-55
pubmed: 18794071
Front Biosci (Landmark Ed). 2009 Jan 01;14:2494-503
pubmed: 19273214
Cancer Res. 2009 Jul 1;69(13):5601-9
pubmed: 19549916
Int J Cancer. 2010 Sep 1;127(5):1081-95
pubmed: 20027628
Curr Pharm Des. 2011;17(19):1944-61
pubmed: 21711235
Oncogene. 2012 Nov 8;31(45):4740-9
pubmed: 22266864
Br J Cancer. 2012 Aug 7;107(4):713-23
pubmed: 22767145
Am J Pathol. 2012 Nov;181(5):1573-84
pubmed: 23022210
Clin Cancer Res. 2013 Apr 1;19(7):1760-72
pubmed: 23287563
Cell Death Dis. 2013 May 23;4:e641
pubmed: 23703386
IUBMB Life. 2013 Oct;65(10):807-18
pubmed: 24030926
Cell Cycle. 2013 Nov 15;12(22):3526-36
pubmed: 24091630
Cell Death Dis. 2013 Oct 24;4:e878
pubmed: 24157872
Cancer Res. 2014 Mar 1;74(5):1598-608
pubmed: 24385215
Asian J Androl. 2014 Jul-Aug;16(4):530-5
pubmed: 24589458
Oncotarget. 2014 Mar 30;5(6):1538-53
pubmed: 24681666
Oncotarget. 2015 Mar 10;6(7):5324-41
pubmed: 25481874
J Extracell Vesicles. 2014 Dec 22;3:26913
pubmed: 25536934
J Biol Chem. 2015 Feb 20;290(8):4545-51
pubmed: 25568317
Oncotarget. 2015 May 10;6(13):11327-41
pubmed: 25857301
Minerva Urol Nefrol. 2015 Sep;67(3):211-31
pubmed: 26054411
Mol Med Rep. 2015 Nov;12(5):6702-10
pubmed: 26299938
Oncotarget. 2015 Sep 22;6(28):25076-92
pubmed: 26312765
Nature. 2015 Nov 19;527(7578):329-35
pubmed: 26524530
Int J Mol Sci. 2016 Feb 06;17(2):175
pubmed: 26861306
J Extracell Vesicles. 2016 Sep 27;5:33109
pubmed: 27680302
Int J Mol Sci. 2016 Dec 06;17(12):
pubmed: 27929432
Cancer Res. 2017 May 1;77(9):2306-2317
pubmed: 28202510
Dev Dyn. 2018 Mar;247(3):382-395
pubmed: 28722327
Cancers (Basel). 2017 Jul 26;9(8):null
pubmed: 28933725
Oncogenesis. 2017 Oct 9;6(10):e388
pubmed: 28991260
J Exp Clin Cancer Res. 2017 Dec 08;36(1):180
pubmed: 29216889
Cell Death Dis. 2018 May 9;9(5):523
pubmed: 29743605
Nat Rev Clin Oncol. 2018 Oct;15(10):617-638
pubmed: 29795272
Nat Rev Cancer. 2018 Sep;18(9):533-548
pubmed: 30002479
Sci Rep. 2018 Aug 13;8(1):12020
pubmed: 30104699
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Cells. 2018 Oct 13;7(10):null
pubmed: 30322133
Stem Cells Int. 2018 Nov 5;2018:6392198
pubmed: 30532788
J Extracell Vesicles. 2018 Nov 23;7(1):1535750
pubmed: 30637094

Auteurs

Chiara Ciardiello (C)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy. c.ciardiello@istitutotumori.na.it.

Alessandra Leone (A)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Paola Lanuti (P)

Centre on Aging Sciences and Translational Medicine (Ce.S.I.-Me.T.), University "G.d'Annunzio", Chieti-Pescara, Italy.
Department of Medicine and Aging Sciences, University "G. d'Annunzio", Chieti-Pescara, Italy.

Maria S Roca (MS)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Tania Moccia (T)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Valentina R Minciacchi (VR)

Georg-Speyer-Haus Institute for Tumor biology and Experimental Therapy, Frankfurt, Germany.

Michele Minopoli (M)

Neoplastic Progression Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.

Vincenzo Gigantino (V)

Pathology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.

Rossella De Cecio (R)

Pathology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.

Massimo Rippa (M)

Institute of Applied Sciences and Intelligent Systems 'E. Caianiello' of CNR, Pozzuoli, Italy.

Lucia Petti (L)

Institute of Applied Sciences and Intelligent Systems 'E. Caianiello' of CNR, Pozzuoli, Italy.

Francesca Capone (F)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Carlo Vitagliano (C)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Maria R Milone (MR)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Biagio Pucci (B)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Rita Lombardi (R)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Federica Iannelli (F)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Elena Di Gennaro (E)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Francesca Bruzzese (F)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy.

Marco Marchisio (M)

Centre on Aging Sciences and Translational Medicine (Ce.S.I.-Me.T.), University "G.d'Annunzio", Chieti-Pescara, Italy.
Department of Medicine and Aging Sciences, University "G. d'Annunzio", Chieti-Pescara, Italy.

Maria V Carriero (MV)

Neoplastic Progression Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Naples, Italy.

Dolores Di Vizio (D)

Departments of Surgery, Pathology & Lab Medicine, and Biochemical Science, Cedars-Sinai Medical Center, Los Angeles, CA, USA.

Alfredo Budillon (A)

Experimental Pharmacology Unit, Istituto Nazionale Tumori - IRCCS- Fondazione G. Pascale, Via M. Semmola, 80131, Naples, Italy. a.budillon@istitutotumori.na.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH